Rifampin: Clinical Overview

Indications

Rifampin is a first-line agent for treating all forms of tuberculosis caused by susceptible organisms 1. It is essential in all short-course TB regimens due to its activity against rapidly dividing bacteria and semidormant populations 1.

Primary Indications:

Drug-susceptible pulmonary tuberculosis (as part of combination therapy) 2
Extrapulmonary tuberculosis (all forms except meningitis requires standard 6-month regimen; meningitis may require longer) 2
Meningococcal carrier state (eradication) 3
Latent TB infection (LTBI) in HIV-infected patients not on protease inhibitors or NNRTIs 4

Adult Dosing Regimens

Active Tuberculosis

Standard dose: 10 mg/kg once daily (maximum 600 mg/day) 3. Weight-based dosing:

<50 kg: 450 mg daily
≥50 kg: 600 mg daily 2

Recommended regimen for drug-susceptible pulmonary TB:

Initial phase (2 months): Rifampin + isoniazid + pyrazinamide + ethambutol daily 2
Continuation phase (4 months): Rifampin + isoniazid daily 2
Total duration: 6 months for most cases 2

Intermittent dosing (twice or three times weekly) is acceptable but requires directly observed therapy (DOT) 2. For intermittent regimens:

Three times weekly: 600 mg per dose 2
Twice weekly: 600 mg per dose 2

Meningococcal Carriers

600 mg twice daily for 2 days 3

Latent TB Infection (LTBI)

For HIV-infected patients not on protease inhibitors/NNRTIs:

Rifampin 600 mg daily for 4 months is an acceptable alternative to isoniazid 5
Rifampin + pyrazinamide for 2 months (at least 60 doses) 4

Administration Instructions

Take rifampin once daily, either 1 hour before or 2 hours after a meal with a full glass of water 3. This is critical because food reduces absorption by approximately 30% 3.

Extemporaneous Oral Suspension (for patients unable to swallow capsules):

Concentration: 10 mg/mL (1% w/v)
Empty contents of four 300 mg capsules (or eight 150 mg capsules) into amber glass or HDPE bottle
Add 20 mL of simple syrup, shake vigorously
Add 100 mL additional syrup, shake well
Stable for 4 weeks at room temperature or refrigerated 3
Shake well before each use

Contraindications

Absolute contraindications:

Hypersensitivity to rifampin or rifamycins 3
Concurrent use with most protease inhibitors (except ritonavir-based regimens or ritonavir + saquinavir) 6
Concurrent use with NNRTIs (except efavirenz) 6

Relative contraindications/special precautions:

Active hepatic disease (use with extreme caution and frequent monitoring) 2
Concurrent use with ritonavir or delavirdine when using rifabutin as alternative 6

Critical Drug Interactions:

Rifampin is a potent CYP450 inducer and substantially reduces levels of:

Protease inhibitors (except specific combinations) 6
NNRTIs (except efavirenz) 6
Warfarin (may require 200% dose increase) 7
Oral contraceptives, anticonvulsants, and many other medications 1

For HIV-infected patients requiring antiretroviral therapy:

Rifampin CAN be used with: efavirenz + 2 NRTIs, ritonavir + NRTIs, or ritonavir + saquinavir 6
Consider rifabutin (with dose adjustments) for other antiretroviral combinations 6

Monitoring Recommendations

Baseline Assessment:

Liver function tests (AST/ALT, bilirubin) 2
Complete blood count 1
Renal function 1
HIV status (affects treatment duration and monitoring) 4

Routine Monitoring:

For patients with normal baseline liver function and no pre-existing liver disease:

No routine laboratory monitoring required 2, 1
Clinical monitoring only: assess for fever, malaise, vomiting, jaundice, or unexplained deterioration 2
Repeat liver function tests immediately if symptoms develop 2

For patients with pre-existing liver disease or abnormal baseline:

If AST/ALT <2× upper limit of normal (ULN): Repeat at 2 weeks, then as needed for symptoms 2
If AST/ALT 2-5× ULN: Monitor weekly for 2 weeks, then every 2 weeks until normal 2
If AST/ALT ≥5× ULN or bilirubin elevated: STOP rifampin, isoniazid, and pyrazinamide immediately 2

Management of Hepatotoxicity:

If drugs must be stopped:

For non-infectious TB in stable patients: wait until liver function normalizes 2
For infectious/severe TB: use streptomycin + ethambutol until liver function normalizes 2

Drug rechallenge protocol (after normalization):

Isoniazid first: 50 mg/day → 300 mg/day over 2-3 days
Then rifampin: 75 mg/day → 300 mg → 450-600 mg (weight-based) over 6-9 days
Finally pyrazinamide: 250 mg/day → 1.0 g → 1.5-2.0 g (weight-based) over 6-9 days
Monitor liver function daily during rechallenge 2

Additional Monitoring:

Universal effects to counsel patients about:

Orange discoloration of bodily fluids (urine, tears, sweat, sputum) is expected and harmless 1
Can permanently stain soft contact lenses 1

Monitor for serious adverse effects:

Hepatotoxicity (most common with rifampin + isoniazid: 2.7% incidence) 1
Flu-like syndrome (0.4-0.7% with intermittent dosing) 1
Severe cutaneous reactions (0.07-0.3%) 1
Thrombocytopenia, hemolytic anemia, acute renal failure (<0.1% each) 1

Special Populations

Renal Insufficiency:

No dose adjustment needed for doses ≤600 mg/day 1, 3. Half-life increases in severe renal failure but does not require modification at standard doses 3.

Hepatic Disease:

Use with extreme caution. Rifampin undergoes hepatic metabolism and can accumulate. More frequent clinical and laboratory monitoring essential 2.

Pregnancy:

Rifampin is considered safe in pregnancy 8. It is a component of standard TB treatment regimens for pregnant women. However, combined preparations containing pyrazinamide (Rifater®) should be avoided in pregnancy 8.

HIV-Infected Patients:

Treatment duration may need extension if clinical or bacteriologic response is slow 9. Close monitoring for treatment failure, paradoxical reactions, and drug interactions is essential 6.

Key Clinical Pearls

Rifampin is irreplaceable in short-course TB therapy; avoid substitution unless absolutely necessary due to drug interactions or intolerance 1
Directly observed therapy (DOT) strongly recommended for all intermittent regimens and should be considered for all patients 2, 9
Orange urine is a useful compliance marker in clinical practice 2
Recent evidence suggests higher doses (25-35 mg/kg) may improve outcomes without increased toxicity, though this is not yet standard practice 10, 11
For complex antiretroviral interactions: consult an expert in TB/HIV co-management 6

What are the indications, adult dosing regimens, administration instructions, contraindications, and monitoring recommendations for rifampin?

Have a follow-up question?